GLP-1 Surge Powers Stevanato Growth as Pulmonx Navigates Sales Restructuring
Key Takeaways
- Stevanato Group reported a 50% surge in GLP-1 related revenue for 2025, underscoring the massive impact of the weight-loss drug market on pharmaceutical supply chains.
- Conversely, medical device maker Pulmonx is undergoing a significant transition following a 50% turnover in its sales organization and a dip in U.S.
- quarterly revenue.
Mentioned
Key Intelligence
Key Facts
- 1Stevanato's GLP-1 related revenue grew by over 50% in 2025, now accounting for 20% of total sales.
- 2High-Value Solutions reached 46% of Stevanato's total revenue, driving a 160bps gross margin expansion.
- 3Pulmonx reported a 50% turnover in its sales organization during 2025, contributing to an 11% U.S. revenue decline in Q4.
- 4Pulmonx secured a $60M credit facility extending debt maturity to 2031, with cash burn projected to drop 30% in 2026.
- 5Stevanato's Biopharmaceutical and Diagnostic Solutions (BDS) segment saw 13% constant currency growth in Q4.
- 6Pulmonx maintained a high gross margin of 77.6% in Q4 despite overall revenue falling 5% year-over-year.
| Metric | ||
|---|---|---|
| Q4 Revenue | $346.5M | $22.6M |
| Revenue Growth (YoY) | +7% | -5% |
| Gross Margin | 30.9% | 77.6% |
| Primary Growth Driver | GLP-1 Packaging | International Expansion |
| Key Operational Challenge | Capacity Constraints | Sales Force Turnover |
Analysis
The fourth-quarter 2025 earnings results for Stevanato Group and Pulmonx reveal a starkly bifurcated landscape within the biopharmaceutical and medical technology sectors. While the 'GLP-1 effect' continues to act as a massive tailwind for companies integrated into the injectable drug supply chain, specialized medical device manufacturers are facing a more challenging environment characterized by sales force restructuring and shifting regional demand. Stevanato Group’s performance serves as a primary bellwether for the broader industry, demonstrating how the explosion in demand for GLP-1 therapies is fundamentally altering the financial profile of pharmaceutical packaging and delivery providers.
Stevanato reported full-year revenue growth of 9% at constant currency, but the true story lies in the mix shift toward High-Value Solutions (HVS). This segment now represents 46% of total company revenue, up significantly from previous years, and contributed to a 160-basis-point expansion in gross profit margins. The primary driver is the GLP-1 category, which now accounts for approximately 20% of Stevanato’s total revenue. The 50% year-over-year growth in this category highlights a critical industry trend: as pharmaceutical giants scale production of weight-loss and diabetes treatments, the bottleneck has shifted to high-precision glass containment and delivery systems. Stevanato’s management noted that capacity for these high-value products was near full utilization throughout 2025, suggesting that future growth will be dictated by the company’s ability to bring new capacity online rather than a lack of market demand.
The company saw worldwide revenue decline by 5% in the quarter, driven largely by an 11% drop in U.S.
What to Watch
In contrast, Pulmonx’s Q4 results illustrate the operational hurdles facing the medical device sector. The company saw worldwide revenue decline by 5% in the quarter, driven largely by an 11% drop in U.S. sales. This downturn coincides with a period of intense internal volatility; CEO Glendon French confirmed that the company experienced a sales organization turnover of approximately 50% over the course of the year. Such a massive restructuring of the commercial team often leads to short-term disruption in hospital account management and procedure volumes. However, Pulmonx is positioning 2026 as a year of re-acceleration, supported by a significant debt refinancing that extends its maturity to 2031 and a projected 30% reduction in annual cash burn. The company’s ability to maintain a high gross margin of 77.6% despite revenue headwinds suggests that the underlying economics of its lung volume reduction technology remain sound, provided it can stabilize its commercial execution.
Looking ahead, the biopharma supply chain appears increasingly tied to the long-term trajectory of metabolic health treatments. Stevanato’s guidance for mid-teens growth in GLP-1 revenue for 2026 reflects a normalization from the triple-digit surges seen in early adoption phases, yet it remains the dominant growth engine for the firm. For the broader medical technology market, Pulmonx’s experience serves as a cautionary tale regarding the importance of sales force stability in a post-pandemic environment where hospital purchasing cycles remain sensitive. Investors and analysts should monitor Stevanato’s capital expenditure efficiency as it expands capacity, while for Pulmonx, the key metric will be the productivity of its newly rebuilt sales force in the first half of 2026. The divergence between these two companies highlights that while the 'macro' healthcare environment is stable, 'micro' sector trends—specifically the GLP-1 boom and medical device commercial restructuring—are the true drivers of alpha in the current cycle.
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |